Literature DB >> 34728799

Systems biological assessment of altered cytokine responses to bacteria and fungi reveals impaired immune functionality in schizophrenia.

Yuan Gao1,2,3, Yajuan Fan1,2,3, Zai Yang1,2,3, Qingyan Ma1,2,3, Binbin Zhao1,2,3, Xiaoyan He1,2,3, Fengjie Gao1,2,3, Li Qian1,2,3, Wei Wang1,2,3, Ce Chen1,2,3, Yunchun Chen1,2,3, Chengge Gao1,2,3, Xiancang Ma4,5,6, Feng Zhu7,8,9,10.   

Abstract

Evidence suggests that complex interactions between the immune system and brain have important etiological and therapeutic implications in schizophrenia. However, the detailed cellular and molecular basis of immune dysfunction in schizophrenia remains poorly characterized. To better understand the immune changes and molecular pathways, we systemically compared the cytokine responses of peripheral blood mononuclear cells (PBMCs) derived from patients with schizophrenia and controls against bacterial, fungal, and purified microbial ligands, and identified aberrant cytokine response patterns to various pathogens, as well as reduced cytokine production after stimulation with muramyl dipeptide (MDP) in schizophrenia. Subsequently, we performed single-cell RNA sequencing on unstimulated and stimulated PBMCs from patients and controls and revealed widespread suppression of antiviral and inflammatory programs as well as impaired chemokine/cytokine-receptor interaction networks in various immune cell subpopulations of schizophrenic patients after MDP stimulation. Moreover, serum MDP levels were elevated in these patients and correlated with the course of the disease, suggesting increased bacterial translocation along with disease progression. In vitro assays revealed that MDP pretreatment altered the functional response of normal PBMCs to its re-stimulation, which partially recapitulated the impaired immune function in schizophrenia. In conclusion, we delineated the molecular and cellular landscape of impaired immune function in schizophrenia, and proposed a mutual interplay between innate immune impairment, reduced pathogen clearance, increased MDP translocation along schizophrenia development, and blunted innate immune response. These findings provide new insights into the pathogenic mechanisms that drive systemic immune activation, neuroinflammation, and brain abnormalities in schizophrenia.
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34728799     DOI: 10.1038/s41380-021-01362-0

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  62 in total

Review 1.  Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010.

Authors:  Harvey A Whiteford; Louisa Degenhardt; Jürgen Rehm; Amanda J Baxter; Alize J Ferrari; Holly E Erskine; Fiona J Charlson; Rosana E Norman; Abraham D Flaxman; Nicole Johns; Roy Burstein; Christopher J L Murray; Theo Vos
Journal:  Lancet       Date:  2013-08-29       Impact factor: 79.321

2.  A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression.

Authors:  D R Goldsmith; M H Rapaport; B J Miller
Journal:  Mol Psychiatry       Date:  2016-02-23       Impact factor: 15.992

3.  Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects.

Authors:  Brian J Miller; Peter Buckley; Wesley Seabolt; Andrew Mellor; Brian Kirkpatrick
Journal:  Biol Psychiatry       Date:  2011-06-08       Impact factor: 13.382

Review 4.  Infectious agents associated with schizophrenia: a meta-analysis.

Authors:  Isabel Arias; Antonio Sorlozano; Enrique Villegas; Juan de Dios Luna; Kathryn McKenney; Jorge Cervilla; Blanca Gutierrez; Jose Gutierrez
Journal:  Schizophr Res       Date:  2011-11-21       Impact factor: 4.939

5.  Impaired glycolytic response in peripheral blood mononuclear cells of first-onset antipsychotic-naive schizophrenia patients.

Authors:  M Herberth; D Koethe; T M K Cheng; N D Krzyszton; S Schoeffmann; P C Guest; H Rahmoune; L W Harris; L Kranaster; F M Leweke; S Bahn
Journal:  Mol Psychiatry       Date:  2010-06-29       Impact factor: 15.992

6.  Cytokine alterations in first-episode schizophrenia patients before and after antipsychotic treatment.

Authors:  Lot de Witte; Jakub Tomasik; Emanuel Schwarz; Paul C Guest; Hassan Rahmoune; René S Kahn; Sabine Bahn
Journal:  Schizophr Res       Date:  2014-02-26       Impact factor: 4.939

7.  Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review.

Authors:  Stéphane Potvin; Emmanuel Stip; Amir A Sepehry; Alain Gendron; Ramatoulaye Bah; Edouard Kouassi
Journal:  Biol Psychiatry       Date:  2007-11-19       Impact factor: 13.382

Review 8.  Maternal immune activation: Implications for neuropsychiatric disorders.

Authors:  Myka L Estes; A Kimberley McAllister
Journal:  Science       Date:  2016-08-19       Impact factor: 47.728

9.  Synaptic loss in schizophrenia: a meta-analysis and systematic review of synaptic protein and mRNA measures.

Authors:  Emanuele Felice Osimo; Katherine Beck; Tiago Reis Marques; Oliver D Howes
Journal:  Mol Psychiatry       Date:  2018-03-06       Impact factor: 15.992

Review 10.  The epidemiologic evidence linking autoimmune diseases and psychosis.

Authors:  Michael E Benros; William W Eaton; Preben B Mortensen
Journal:  Biol Psychiatry       Date:  2013-10-03       Impact factor: 13.382

View more
  4 in total

Review 1.  Progresses in GluN2A-containing NMDA Receptors and their Selective Regulators.

Authors:  Menghan Niu; Xin Yang; Yuanyuan Li; Yanping Sun; Long Wang; Jing Ha; Yinghua Xie; Zibin Gao; Changzheng Tian; Le Wang; Yongjun Sun
Journal:  Cell Mol Neurobiol       Date:  2022-01-03       Impact factor: 5.046

Review 2.  COVID-19 exit strategy during vaccine implementation: a balance between social distancing and herd immunity.

Authors:  Suhad Daher-Nashif; Rania Al-Anany; Menatalla Ali; Khadija Erradi; Elmoubasher Farag; Abdallah M Abdallah; Mohamed M Emara
Journal:  Arch Virol       Date:  2022-06-20       Impact factor: 2.685

3.  COVID-19 and mental health: a longitudinal population study from Norway.

Authors:  Hans K Hvide; Julian Johnsen
Journal:  Eur J Epidemiol       Date:  2022-01-27       Impact factor: 8.082

4.  The impact of the UK COVID-19 pandemic on patient-reported health outcomes after stroke: a retrospective sequential comparison.

Authors:  Hatice Ozkan; Gareth Ambler; Gargi Banerjee; Edgar Chan; Simone Browning; John Mitchell; Richard Perry; Alex P Leff; Robert J Simister; David J Werring
Journal:  J Neurol       Date:  2021-10-15       Impact factor: 4.849

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.